Holen Sie sich die Stockscreener-App
17.34
3.34%
0.56
Handel nachbörslich:
17.34
Schlusskurs vom Vortag:
$16.78
Offen:
$16.47
24-Stunden-Volumen:
1.04M
Relative Volume:
0.60
Marktkapitalisierung:
$2.10B
Einnahmen:
$631.73M
Nettoeinkommen (Verlust:
$-239.78M
KGV:
-9.0785
EPS:
-1.91
Netto-Cashflow:
$-33.45M
1W Leistung:
+9.82%
1M Leistung:
-13.39%
6M Leistung:
-36.90%
1J Leistung:
-56.34%
1-Tages-Spanne:
$16.35
$17.36
1-Wochen-Bereich:
$15.02
$17.36
52-Wochen-Spanne:
$14.02
$57.90
10 X Genomics Inc Stock (TXG) Company Profile
Firmenname
10 X Genomics Inc
Sektor
Branche
Telefon
(925) 401-7300
Adresse
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-12-14 | Eingeleitet | Guggenheim | Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2023-07-05 | Fortgesetzt | JP Morgan | Overweight |
| 2023-05-10 | Eingeleitet | Barclays | Overweight |
| 2023-03-31 | Eingeleitet | Stephens | Overweight |
| 2023-02-02 | Eingeleitet | UBS | Neutral |
| 2022-12-14 | Eingeleitet | Deutsche Bank | Buy |
| 2022-08-18 | Herabstufung | Goldman | Neutral → Sell |
| 2022-07-25 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-07-15 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-07-15 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2021-10-15 | Fortgesetzt | Cowen | Outperform |
| 2021-09-14 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-03-15 | Eingeleitet | William Blair | Outperform |
| 2020-12-02 | Eingeleitet | Goldman | Neutral |
| 2020-09-09 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-07-10 | Eingeleitet | Stifel | Buy |
| 2020-03-05 | Eingeleitet | Guggenheim | Buy |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2019-10-07 | Eingeleitet | BofA/Merrill | Buy |
| 2019-10-07 | Eingeleitet | Cowen | Outperform |
| 2019-10-07 | Eingeleitet | JP Morgan | Overweight |
| 2019-09-24 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
10 X Genomics Inc Aktie (TXG) Neueste Nachrichten
10x Genomics Inc (TXG) Trading 2.45% Higher on Nov 4 - GuruFocus.com
10x Genomics (NASDAQ:TXG) Price Target Cut to $19.00 by Analysts at Barclays - MarketBeat
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts - Simply Wall St
FY2024 EPS Estimates for 10x Genomics Boosted by Analyst - MarketBeat
Allspring Global Investments Holdings LLC Has $880,000 Stake in 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative - PR Newswire
10x Genomics, Inc. (NASDAQ:TXG) Q3 2024 Earnings Call Transcript - Insider Monkey
TechBio Startup Cure51 Selects 10x Genomics Visium HD for New Drug Discovery Initiative – Company Announcement - Financial Times
10x Genomics Inc (TXG) Q3 2024 Earnings Call Highlights: Navigat - GuruFocus.com
These Analysts Boost Their Forecasts On 10x Genomics After Q3 Results - Benzinga
10x Genomics Inc (TXG) Trading 4.91% Higher on Oct 30 - GuruFocus.com
UBS Group Lowers 10x Genomics (NASDAQ:TXG) Price Target to $20.00 - MarketBeat
10x Genomics (NASDAQ:TXG) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat
10x Genomics Inc (TXG) Q3 2024 Earnings Call Highlights: Navigating Challenges with Strategic ... - Yahoo Finance
10x Genomics: Q3 Earnings Snapshot - The Advocate
10x Genomics (TXG) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
10x Genomics falls 7% on 2024 revenue guidance cut - MSN
10x Genomics (TXG) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
10x Genomics Inc Reports Q3 2024 Revenue of $151.7 Million, Missing Estimates; Gross Margin Improves to 70% - GuruFocus.com
10x Genomics shares sink 7% on revenue miss, lowered outlook - Investing.com India
10x Genomics shares sink 7% on revenue miss, lowered outlook By Investing.com - Investing.com UK
10x Genomics, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year of 2024 - Marketscreener.com
10x Genomics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
10x Genomics Reports Third Quarter 2024 Financial Results – Company Announcement - Financial Times
Zacks Industry Outlook Medical Systems, 10x Genomics and Omnicell - Yahoo Finance
10X Genomics' SWOT analysis: stock faces headwinds amid strong consumables demand - Investing.com India
Lecap Asset Management Ltd. Purchases Shares of 38,829 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics (TXG) Upgraded to Strong Buy: Here's Why - Yahoo Finance
PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program - StockTitan
10x Genomics (TXG) Set to Announce Earnings on Tuesday - MarketBeat
Morgan Stanley spotlights 10 small-cap stocks with at least 50% upside - Kursiv Media
10x Genomics Inc.: How Are They Adapting to Market Conditions & Customer Needs?Major Drivers - Smartkarma
European Unified Patent Court Rules in Favor of Bruker and NanoString, Invalidating Patent Asserted By 10x Genomics against NanoString’s CosMx SMI Products - Yahoo Finance
Analysts Set 10x Genomics, Inc. (NASDAQ:TXG) Target Price at $30.60 - MarketBeat
SG Americas Securities LLC Sells 77,766 Shares of 10x Genomics, Inc. (NASDAQ:TXG) - MarketBeat
10x Genomics Delivers 'Single Cell for a Single Cent' with New Chromium Launches - PR Newswire
Barclays Lowers 10x Genomics (NASDAQ:TXG) Price Target to $21.00 - MarketBeat
10x Genomics, Inc. to Post Q3 2024 Earnings of ($0.31) Per Share, Leerink Partnrs Forecasts (NASDAQ:TXG) - MarketBeat
10x Genomics Stock: Deciphering The Preliminary Q3 Earnings (NASDAQ:TXG) - Seeking Alpha
The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28% - Simply Wall St
10X Genomics stock hits 52-week low at $14.91 amid market shifts - Investing.com India
10x Genomics reports dip in Q3 instrument sales, growth in consumables By Investing.com - Investing.com Australia
These Stocks Are Moving the Most Today: Tesla, Super Micro, AMD, and More - Barron's
10x Genomics reports dip in Q3 instrument sales, growth in consumables - Investing.com India
Where 10x Genomics Stands With Analysts - Benzinga
10x Genomics' (TXG) Overweight Rating Reiterated at Stephens - MarketBeat
10x Genomics (NASDAQ:TXG) PT Lowered to $20.00 - MarketBeat
10x Genomics (NASDAQ:TXG) Reaches New 1-Year LowShould You Sell? - MarketBeat
10X Genomics stock hits 52-week low at $14.91 amid market shifts By Investing.com - Investing.com South Africa
Tesla, Delta, Super Micro, 10x Genomics, Domino’s, TD Bank, and More Stock Movers - Barron's
Gene Sequencing Tech Provider 10x Genomics' Q3 Sales Fall Short On Expectations, But CEO Sees Opportunity Ahead - Benzinga
Finanzdaten der 10 X Genomics Inc-Aktie (TXG)
Umsatz
Nettogewinn
Free Cashflow
ENV
10 X Genomics Inc-Aktie (TXG) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hindson Benjamin J. | See Remarks |
Aug 22 '24 |
Sale |
22.53 |
4,351 |
98,027 |
345,704 |
| McAnear Justin J. | Former Chief Financial Officer |
Aug 22 '24 |
Sale |
22.53 |
2,961 |
66,710 |
143,242 |
2.66%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):